One of my biggest cannabis public policy pet peeves is when governments institute THC percentage caps on products, primarily due to the negative impact it has on the suffering patients that desperately need cannabis products containing higher amounts of THC. I extend my distain for THC percentage caps to the adult-use industry because whether people realize it or not, many suffering patients obtain their medicine via the adult-use industry when possible, including in Uruguay where low-THC percentage limits have been in place in pharmacies since legal sales began in 2017.
Uruguay first passed a national adult-use legalization measure back in 2013, making it the first country on the planet to do so since the dawn of prohibition. The historic legalization measure provided for various ways for consumers to obtain cannabis, including private clubs and home cultivation. It also provided for eventual legal sales through pharmacies for two varieties of cannabis flower, “alpha” and “beta” flower. Both options have a THC level of less than or equal to 9% and a CBD level of greater than or equal to 3%. Thankfully, a third option is on the way, and the cannabinoid limits are much more favorable.
“Gamma” Cannabis Flower
Juan Ignacio Tastás, the executive director of the Institute for the Regulation and Control of Cannabis (Ircca), announced recently that Uruguay is set to launch a third variety of cannabis to be sold through pharmacies. The new variety is called “gamma” and will contain a THC percentage that is less than or equal to 15%, and a CBD percentage that is less than or equal to 1%. The new option is expected to be available to consumers in Uruguay starting around December 20th.
To put things into perspective, cannabis flower that tops 30% THC is common in many legal states in the U.S. and in Canada. For some consumers, anything less than 30% is often deemed as not being strong enough. For patients, especially those that suffer from chronic and severe pain, high-potency cannabis flower is an optimal form of medicine.
A huge benefit of adult-use legalization is that patients don’t have to jump through all the hoops of a medical cannabis program to obtain their medicine. In Uruguay, they simply must be of legal age and go to a licensed pharmacy that sells adult-use cannabis. However, that only works out if the pharmacy actually sells cannabis that is strong enough to help the suffering patient.
An Evolving Model
Part of the reporting out of Uruguay indicates that yet another strain, a fourth option, is being considered for pharmacies, with a potential release date being next December. No details seem to be available regarding what cannabinoid levels will be involved. It’s definitely possible that an option with an even higher level of THC could be involved, however, without any details surfacing I suppose it’s also possible that it could be a low-THC, high-CBD strain. We will all just have to wait and see.
One thing that is clear is that Uruguay’s adult-use cannabis regulation model, the first one in the history of the world at a national level, is still evolving. That provides a learning moment for other countries that are exploring which components to include and exclude for their legalization frameworks. Lawmakers and regulators in those countries need to approach cannabinoid level limits objectively. By doing so they will no doubt realize that THC percentage limits do not serve any actual scientific purpose, but rather, are born out of reefer madness and as a result they should never be a part of any sensible cannabis public policy.
This article first appeared at Internationalcbc.com and is syndicated with special permission
Follow Johnny Green on social media: @RealJohnny Green on LinkedIn, Twitter, Instagram, Facebook, Social Club and at: YouTube.com/c/TheHigherThingsClub
Johnny Green is the Media and Content Director for the International Cannabis Business Conference. Upcoming conferences include Rovinj, Croatia (September 22-23, 2022), Barcelona (March 9, 2023), Berlin Global Investment Forum (June 27, 2023), and Berlin B2B Trade Show (June 29-30, 2023).